Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study

Cancer

Volumn 120, Issue 11, 2014, Pages 1630-1638

  Booth, Christopher M ^a,b   Siemens, D Robert ^b   Li, Gavin ^a   Peng, Yingwei ^a,b   Tannock, Ian F ^c   Kong, Weidong ^a   Berman, David M ^b   Mackillop, William J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

bladder cancer; chemotherapy; health services research; knowledge translation; outcomes; quality of care

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COMORBIDITY; CYSTECTOMY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; TREND STUDY; VERY ELDERLY; YOUNG ADULT;

BLADDER CANCER; CHEMOTHERAPY; HEALTH SERVICES RESEARCH; KNOWLEDGE TRANSLATION; OUTCOMES; QUALITY OF CARE;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84901308771     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28510     Document Type: Article

References (30)

1. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK,. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171-2177.
2. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
3. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005; 48 2: 202-205.
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol. 2005; 48 2: 189-199.
5. Ruggeri EM, Giannarelli D, Bria E, et al. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer. 2006; 106: 783-788.
6. Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012; 62: 523-533.
7. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012; 23: 695-700.
8. Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group 99/01 study. J Clin Oncol. 2010; 28.
9. European Organization for Research and Treatment of Cancer. Randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4, and/or N+M0 transitional cell carcinoma (TCC) of the bladder. EORTC Trial 30994, ed. Available at: http://www.eortc.be/ clinicaltrials/details.asp?protocol=30994. Accessed May 9, 2013.
10. Mackillop WJ,. Health services research in radiation oncology: toward achieving the achievable. In:, Gunderson LL, Tepper JE, eds. Clinical Radiation Oncology. Philadelphia: Churchill Livingstone; 2007: 215-237.
11. Meyer RM,. Generalizing the results of cancer clinical trials. J Clin Oncol. 2010; 28: 187-189.
12. Booth CM, Mackillop WJ,. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA. 2008; 300: 2177-2179.
13. Clarke EA, Marrett LD, Krieger N,. Cancer registration in Ontario: a computer approach. In:, Jenson OM, Parkin DM, MacLennan R, eds. Cancer Registration Principles and Methods. Lyon, France: IARC, 1991: 246-257.
14. Booth CM, Li G, Zhang-Salomons J, Mackillop WJ,. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada. Cancer. 2010.
15. Williams J, Young W,. A summary of studies on the quality of health care administrative databases in Canada. In:, Goel V, Williams JI, Anderson GM, et al, eds. Patterns of Health Care in Ontario: The ICES Practice Atlas. Ottawa, Ontario, Canada: Canadian Medical Association,; 1996: 339-345.
16. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
17. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC,. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001; 19: 1064-1070.
18. Rubin DB,. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127: 757-763.
19. Winquist E, Waldron T, Segal R, Chin J, Likka H,. Use of neoadjuvant chemotherapy in transitional cell carcinoma of the bladder Practice Guideline Report #3-2-2. Cancer Care Ontario Program in Evidence-Based Care, ed. Available at: https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/genito- ebs/. Accessed May 9, 2013.
20. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007; 69 (1 Suppl): 62-79.
21. Segal R, Winquist E, Lukka H, et al. Use of Adjuvant Chemotherapy Following Cystectomy in Patients with Deep Muscle-Invasive Transitional Cell Carcinoma of the Bladder.
22. Practice Guideline Report #3-2-1. Cancer Care Ontario Program in Evidence-Based Care, ed. Available at: https://www.cancercare.on.ca/toolbox/ qualityguidelines/diseasesite/genito-ebs/. Accessed May 9, 2013.
23. Juffs HG, Moore MJ, Tannock IF,. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol. 2002; 3: 738-747.
24. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM,. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007; 178: 451-454.
25. Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005; 65: 1118-1125.
26. Porter MP, Kerrigan MC, Donato BMK, et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011; 29: 252-258.
27. Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010; 16: 4461-4467.
28. Goossens-Laan CA, Gooiker GA, van GW, et al. A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate. Eur Urol. 2011; 59: 775-783.
29. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351543-551.
30. Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol. 2010; 28: 3472-3478.